Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study (Adv. Sci. 40/2025)
Year: 2025
Type: article
Abstract: Second-Line Therapy For anti-angiogenic tyrosine kinase inhibitors as second-line treatment in gastric cancer, available biomarker is still unavailable. In their Research Article (DOI: 10.1002/advs.202506678), Feng Qi, Jun Zhang, and co-workers perform an exploratory investigation by using dynamic network biomarker method and find it can be used to guide patient selection of lenvatinib plus paclitaxel in second-line treatment of gastric cancer. The picture shows that the dynamic network biomarker score can provide efficacy-related information to doctors and help them select suitable therapy for their patients, which likes a signboard at the middle of a T-junction.
Source: Advanced Science
DOI: 10.1002/advs.71957
Authors: Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,730
OpenAlex ID: W7101454929